Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CFT8634 |
Synonyms | |
Therapy Description |
CFT8634 binds to BRD9 and E3 ligase, leading to degradation of Brd9 and potentially resulting in decreased tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr ND09). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CFT8634 | CFT-8634|CFT 8634 | CFT8634 binds to BRD9 and E3 ligase, leading to degradation of Brd9 and potentially resulting in decreased tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr ND09). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05355753 | Phase Ib/II | CFT8634 | A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors | Terminated | USA | 0 |